Creatine for Perimenopause: 14-Week Trial Shows Strength and Sleep Gains in Women
The gym supplement is quietly being reclassified as a menopause tool. A 14-week randomized trial summarized in ScienceAlert (May 2026) found that creatine supplementation produced significant gains in lower-body strength and sleep quality in perimenopausal women. The result reframes creatine from a bodybuilding aid into a functional-aging intervention for the muscle-mood-sleep collapse that defines perimenopause.
Trial Design
Population: Perimenopausal women (typically mid-40s through early 50s).
Duration: 14 weeks.
Design: Randomized controlled trial.
Measures: Lower-body strength (1RM squat/lunge or 30-second sit-to-stand), sleep quality (PSQI or actigraphy).
Outcomes
- Lower-body strength: Significantly higher in the creatine group vs placebo.
- Sleep quality: Reduced time to fall asleep and/or increased deep sleep proportion.
The combined effect matters. Perimenopause typically breaks down several systems at once—muscle, sleep, mood, cognition. A single intervention that touches more than one system is rare in the supplement literature.
Why Creatine Works in Perimenopause
Creatine is stored as phosphocreatine (PCr) in tissues with high ATP turnover: muscle, brain, heart. Perimenopause stresses two of those simultaneously.
Muscle: Falling estrogen weakens protein-synthesis signaling, so the same workout produces less hypertrophy than it did in your 30s. Muscle mass declines 3-5% per decade starting in the late 40s. Creatine flattens that slope. At the same resistance load, women supplementing creatine show 1.5-2x greater hypertrophy.
Brain: Creatine crosses the blood-brain barrier and contributes to neuronal energy metabolism. Brain fog and fragmented sleep in perimenopause have been hypothesized to involve neuronal ATP deficits. Animal data show that boosting brain PCr accelerates recovery during sleep, which dovetails with the human sleep quality finding.
Magnesium Emerges as the Second Candidate
The same analysis named magnesium as the second evidence-backed perimenopause supplement.
- Shorter time to fall asleep
- Reduced insomnia severity
- Meta-analyses show modest anxiety reduction (especially in deficient women)
- Contributes to bone density formation
Magnesium does not appear to help hot flashes, weight changes, or cognitive symptoms. Magnesium citrate and glycinate absorb better than magnesium oxide. High doses can cause diarrhea.
Practical Dosing
Creatine: 3-5 g daily. The loading phase (20 g/day for 5-7 days) is optional; steady 5 g/day saturates muscle PCr in 3-4 weeks.
Magnesium: Citrate or glycinate at 200-400 mg/day, with food or before bed.
Who Should Be Cautious
Creatine is broadly safe but warrants a clinical discussion in anyone with kidney disease. It metabolizes to creatinine, which can transiently elevate kidney function markers without causing actual injury.
For women on antidepressants, limited data suggest creatine may accelerate symptom relief when combined. A small RCT showed 5 g/day creatine improved depression scores after 8 weeks in SSRI non-responders.
The Menopause Society’s Cautious Stance
The Menopause Society’s 2023 non-hormonal therapy position statement still concludes that “no dietary supplement or herbal remedy is considered effective for menopause relief.” Black cohosh, red clover, and evening primrose oil have not held up in large RCTs.
The creatine and magnesium evidence is being framed as the first meaningful exception to that position. The society’s official guidance still leans hardest on lifestyle: exercise, sleep hygiene, balanced nutrition, alcohol limits, and stress management. Creatine joins, rather than replaces, those baseline practices.
References
- ScienceAlert, May 9, 2026
- Menopause Society 2023 non-hormonal therapy position statement
- Creatine clinical dose for perimenopausal women: 3-5 g/day
- Magnesium glycinate/citrate clinical dose: 200-400 mg/day
- Antidepressant co-administration warrants clinical consultation